• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Korea·Industrials·003580.KS
Share

HLB GLOBAL Co., Ltd. Stocks

₩ 1958Last Updated 16.10.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

₩ 100.11M

₩ 1958
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Headquartered in Sabuk-eup, South Korea, HLB GLOBAL Co., Ltd., established in 1962, primarily engages in marine sand extraction operations within South Korea. Their detailed process for producing sea sand encompasses vessel departure, underwater recovery, port berthing, cargo offloading, meticulous sorting, washing, and subsequent shipment. Beyond sand, the company also procures a range of other aggregates from the seabed, including gravel, mixed and fine aggregates, asphalt, and concrete. Diversifying its business, HLB GLOBAL markets a variety of consumer goods, specifically color cosmetics, hair care products, and denim apparel, in the United States, China, and Japan. Furthermore, the company is actively involved in drug development, focusing on treatments for infectious illnesses such as sepsis, influenza, and viral hepatitis, alongside immunological disorders like rheumatoid arthritis. The entity was formerly known as NEXT SCIENCE Co., Ltd. until its rebranding to HLB GLOBAL Co., Ltd. in April 2022.

Company Valuation

Overvalued
2/7

From both historical and forecast perspectives, the stock is overpriced compared to similar stocks.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

17.10.2026 16:01

Small-Cap Highlights: Russell 2000 Drops, Bumble Sells Off, Crocs Shines

17.10.2026 13:01

The Weak Link in the AI Revolution: Big Pharma Comes to the Rescue of Investors; Burry Believes in Mortgages

17.10.2026 03:47

"It'll all blow over": Nvidia CEO Huang expressed confidence that the AI rally will continue

17.10.2026 03:37

"Musk Magic" Is Back: CFRA Analyst Raises Tesla's Price Target Due to the Flying Car

17.10.2026 03:20

Citi and BofA block AI agents from client accounts amid fears of deposit outflows

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026